8-fluoroisoquinoline 2-oxide | 1008-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 8-fluoroisoquinoline 2-oxide
• 英文别名: 8-Fluoro-2-oxidoisoquinolin-2-ium
• CAS: 1008-23-7
• 化学式: C₉H₆FNO
• 分子量: 163.151
• InChiKey: DVJNKIMVJOJLJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-fluoroisoquinoline 2-oxide 在 titanium(IV) isopropylate 、 bis-triphenylphosphine-palladium(II) chloride 、 sodium acetate 、 pyridinium hydrobromide perbromide 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 59.0h， 生成 2-((1-(8-fluoro-1-oxo-1,2-dihydroisoquinolin-4-yl)ethyl)amino)ethane-1-sulfonamide
  参考文献：
  名称：

  WO2020123674A5

  摘要：

  公开号：

  WO2020123674A5
• 作为产物：
  描述：

  (2-fluorobenzylidene)(2,2-dimethoxyethyl)amine 在 硫酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 8-fluoroisoquinoline 2-oxide
  参考文献：
  名称：

  Synthesis of novel substituted isoquinolones

  摘要：

  A series of novel substituted isoquinolones have been synthesised. This has been achieved by two routes, either Curtius rearrangment of cinnamic acids or via an isoquinoline N-oxide. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00573-2

文献信息

• Non-natural nucleotides and dinucleotides
  申请人：——

  公开号：US20040122223A1

  公开（公告）日：2004-06-24

  Nucleotide derivatives of formula (1) are described: wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non-natural nucleoside as defined herein; G′ is a non-natural necleoside as defined herein; n is zero, or the integer 1 or 2; m is zero or the integer 1 or 2; and the salts, solvates, hydrates and N-oxides thereof. The compounds are P2Y receptor agonists and are of use in the prophylaxis and treatment of diseases and disorders involving abnormal secretory mechanisms such as inadequate functioning of mucociliary clearance mechanisms or abnormal tear secretion or in the treatment of diseases involving inappropriate cellular glucose uptake.

  公式（1）的核苷酸衍生物被描述如下：其中：G是氢原子或可选择取代的脂肪，杂脂肪，环脂肪，多环脂肪，芳香或杂芳基团或非天然核苷酸，如此处所定义；G'是如此处所定义的非天然核苷酸；n为零或整数1或2；m为零或整数1或2；以及其盐，溶剂化合物，水合物和N-氧化物。这些化合物是P2Y受体激动剂，用于预防和治疗涉及异常分泌机制的疾病和障碍，如粘液纤毛清除机制功能不足或泪液分泌异常，或用于治疗涉及不适当的细胞葡萄糖摄取的疾病。
• NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES
  申请人：Celltech R & D Limited

  公开号：EP1368366A1

  公开（公告）日：2003-12-10
• SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME
  申请人：Arbutus Biopharma Corporation

  公开号：EP3893645A1

  公开（公告）日：2021-10-20
• [EN] NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES<br/>[FR] NUCLEOTIDES ET DINUCLEOTIDES NON NATURELS
  申请人：CELLTECH R&D LTD

  公开号：WO2002062816A1

  公开（公告）日：2002-08-15

  Nucleotide derivatives of formula (1) are described: wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non-natural nucleoside as defined herein; G' is a non-natural necleoside as defined herein; n is zero, or the integer 1 or 2; m is zero or the integer 1 or 2; and the salts, solvates, hydrates and N-oxides thereof. The compounds are P2Y receptor agonists and are of use in the prophylaxis and treatment of diseases and disorders involving abnormal secretory mechanisms such as inadequate functioning of mucociliary clearance mechanisms or abnormal tear secretion or in the treatment of diseases involving inappropriate cellular glucose uptake.
• [EN] SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME<br/>[FR] ARYLMÉTHYLURÉES ET HÉTÉROARYLMÉTHYLURÉES SUBSTITUÉES, ANALOGUES DE CES DERNIÈRES ET PROCÉDÉS D'UTILISATION DE CELLES-CI
  申请人：ARBUTUS BIOPHARMA CORP

  公开号：WO2020123674A1

  公开（公告）日：2020-06-18

  The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.